Composite Hydroxide Gastric Mucosa Protection

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Proton pump inhibitors, while effective in inhibiting gastric acid secretion, have high recurrence rates of ulcers upon cessation and side effects such as shock, hematopathy, and visual disturbances, and neglect the therapeutic value of mucosa protection factors due to long-term use.

Innovation Solution

A composite hydroxide therapeutic agent with a positively-charged surface, comprising magnesium and aluminum hydroxide, which strongly adsorbs to the gastric mucosa, forms highly-dispersible fine particles, and slowly dissolves in gastric acid to provide long-term mucosa protection without inhibiting gastric acid secretion.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If proton pump inhibitors are used to inhibit gastric acid secretion, then ulcer attack factors are eliminated, but recurrence rate of ulcer increases and side effects occur

Engineering Contradiction:
Improveulcer attack factorsVSAvoidrecurrence rate of ulcer
Core Design Contradiction:
Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent converts the harmful effect of proton pump inhibitors (complete inhibition of gastric acid secretion) into a benefit by using composite hydroxide that slowly dissolves in gastric acid to provide sustained protection. The composite hydroxide neutralizes gastric acid gradually without completely blocking secretion, thereby preventing ulcer recurrence while maintaining safety.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The patent changes the parameter of gastric acid neutralization from complete inhibition (proton pump inhibitors) to gradual neutralization (composite hydroxide). By controlling the dissolution rate of the composite hydroxide, it provides sustained protection against gastric acid without causing the harmful effects associated with complete inhibition.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If proton pump inhibitors are used for long period, then ulcer therapy effect is achieved, but excess formation of ECL cell and cavitation of wall cell occur

Engineering Contradiction:
Improveulcer therapy effectVSAvoidexcess formation of ECL cell
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of long-term proton pump inhibitor use (excess ECL cell formation) into a benefit by using composite hydroxide that provides sustained protection without completely inhibiting gastric acid secretion. The gradual dissolution of composite hydroxide maintains a balance that prevents ECL cell hyperplasia while maintaining ulcer protection.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

3Object-affected harmful factors

If proton pump inhibitors are used, then gastric acid secretion is inhibited, but side effects such as shock, hematopathy or visual disturbance occur

Engineering Contradiction:
Improvegastric acid secretion inhibitionVSAvoidside effects
Core Design Contradiction:
Object-affected harmful factorsVSObject-generated harmful factors

Solution Approach 1:

The patent converts the harmful effect of proton pump inhibitors (complete gastric acid secretion inhibition) into a benefit by using composite hydroxide that slowly dissolves to provide gradual neutralization. This approach maintains gastric acid secretion while providing sufficient protection against ulcers, thereby eliminating side effects associated with complete inhibition.

Inventive Principle:
Principle #22Blessing in disguise (Convert harm into benefit)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The agent effectively protects the gastric mucosa from acid attacks, offering a safer and more effective therapy than proton pump inhibitors with reduced recurrence rates and no side effects, while maintaining antacid properties and promoting cell repair.

Implementation Method 1

a composite hydroxide therapeutic agent with a positively-charged surface, comprising magnesium and aluminum hydroxide, which strongly adsorbs to the gastric mucosa

Methodology Applied
Scientific EffectAdsorption: Adsorption

Implementation Method 2

slowly dissolves in gastric acid to provide long-term mucosa protection

Methodology Applied
Scientific EffectDissolution: Solvation

Implementation Method 3

making gastric acid harmless by means of neutralization

Methodology Applied
Scientific EffectNeutralization: Chemical Bonding

Data Source

PatentUS8974835B2Gastric ulcer therapeutic agent
Publication Date: 2015.03.10 SETOLAS HLDG INC

AI summary

A gastric ulcer therapeutic agent comprising as an active ingredient a composite hydroxide of a hydrotalcite and an aluminum hydroxide compound, which composite hydroxide is represented by the formula (1),Mg1-xAlx(OH)2+x-ny(An-)y(H2O)m  (1),wherein An-represents an anion, n represents a valence of the anion in the range of 1 to 4, x is in the range of 0.34<x<0.7, y is in the range of 0<y<0.8, and m is in the range of 0<m<4.